文献速递临床微生物质量管理与危急值

头孢地尔肉汤微量稀释法与纸片扩散法药敏解释一致性比较:CLSI、EUCAST与FDA标准

Interpretive agreement of susceptibility between broth microdilution and disk diffusion methods for cefiderocol, using criteria from the Clinical and Laboratory Standards Institute, European Committee on Antimicrobial Susceptibility Testing, and the Food and Drug Administration.
PubMed 文献 · J Clin Microbiol · 2025-12-10

本研究评估头孢地尔(FDC)肉汤微量稀释法(BMD)与纸片扩散法(DD)在多种革兰阴性杆菌中的分类一致性(CA),以MIC解释为参考,比较CLSI、EUCAST和FDA折点。共纳入1170株革兰阴性杆菌,包括碳青霉烯耐药(CR)和碳青霉烯敏感(CS)菌株。结果显示CLSI折点下DD与BMD一致性最高,FDA标准除鲍曼不动杆菌复合体外表现相当,EUCAST折点变异性较大。

要点

  • CLSI折点下DD与BMD分类一致性最高,CR菌株中CA为90.0%–100%。
  • FDA标准除鲍曼不动杆菌复合体外与CLSI表现相当,该菌CA为63.0%。
  • EUCAST折点变异性较大,CR菌株中CA为66.7%–100%。

核心结论

  • CLSI折点下纸片扩散法与肉汤微量稀释法对头孢地尔的解释一致性最高。
  • FDA标准除鲍曼不动杆菌复合体外与CLSI表现相当,EUCAST折点变异性较大。

研究设计与样本

  • 研究纳入1170株革兰阴性杆菌,包括大肠埃希菌、肺炎克雷伯菌、产酸克雷伯菌、阴沟肠杆菌复合群、铜绿假单胞菌和鲍曼不动杆菌-醋酸钙复合体的CR与CS菌株。
  • 另纳入嗜麦芽窄食单胞菌、洋葱伯克霍尔德菌和Elizabethkingia anophelis等不按碳青霉烯敏感性分类的菌株。
  • 以MIC解释为参考,计算纸片扩散法与肉汤微量稀释法的分类一致性和错误率(minor error、major error、very major error)。

主要发现

  • CR菌株中,基于CLSI折点的CA在各菌种间为90.0%至100%。
  • CR菌株中,FDA标准除鲍曼不动杆菌-醋酸钙复合体CA较低(63.0%)外表现相当;EUCAST折点CA为66.7%至100%。
  • CS菌株中,多数标准和菌种的CA≥87.5%,例外包括EUCAST在阴沟肠杆菌复合群(63.0%)和FDA在鲍曼不动杆菌-醋酸钙复合体(73.7%)。

关键数值与推荐

  • CR菌株中CLSI折点下DD与BMD的CA范围为90.0%–100%。
  • CR菌株中FDA标准下鲍曼不动杆菌-醋酸钙复合体CA为63.0%。
  • CR菌株中EUCAST折点下CA范围为66.7%–100%。
  • CS菌株中多数标准和菌种CA≥87.5%,EUCAST在阴沟肠杆菌复合群为63.0%,FDA在鲍曼不动杆菌-醋酸钙复合体为73.7%。

临床怎么用

  • 临床实验室采用纸片扩散法检测头孢地尔药敏时,优先参考CLSI折点以提高与BMD的一致性。
  • 对鲍曼不动杆菌-醋酸钙复合体,使用FDA或EUCAST折点解释纸片扩散法结果需警惕分类不一致风险。
  • 对阴沟肠杆菌复合群,使用EUCAST折点解释纸片扩散法结果需注意CA较低(63.0%)。

局限性

  • 原文未报告错误率(minor error、major error、very major error)的具体数值。
  • 原文未报告各菌种具体样本量及统计学检验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Cefiderocol (FDC) is a siderophore cephalosporin approved for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (MDR-GNB), including carbapenem-resistant (CR) isolates. However, interpretation criteria for both broth microdilution (BMD) and disk diffusion (DD) methods differ among Clinical and Laboratory Standards Institute (CLSI), European Committee on Antimicrobial Susceptibility Testing (EUCAST), and U.S. Food and Drug Administration (FDA) guidelines. This study aimed to assess the categorical agreement (CA) between minimum inhibitory concentrations (MICs) determined by the BMD method and inhibition zone diameters measured by the DD method for FDC, using different interpretive breakpoints across various Gram-negative bacilli (GNB) isolates. A total of 1,170 GNB isolates were collected, including CR and carbapenem-susceptible (CS) isolates of Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Pseudomonas aeruginosa, and Acinetobacter baumannii-calcoaceticus complex. Isolates of Stenotrophomonas maltophilia, Burkholderia cepacia, and Elizabethkingia anophelis-which are not categorized by carbapenem susceptibility-were also included. The CA and error rates (minor error, major error, and very major error) were calculated using MIC interpretation as the reference. Among CR isolates, CA based on CLSI breakpoints ranged from 90.0% to 100% across species. U.S. FDA criteria showed comparable performance, except for A. baumannii-calcoaceticus complex, where CA was lower (63.0%). In contrast, EUCAST breakpoints demonstrated greater variability, with CA ranging from 66.7% to 100%. Among CS isolates, CA was generally high (≥87.5%) across most standards and species, with exceptions including EUCAST in the E. cloacae complex (63.0%) and U.S. FDA in A. baumannii-calcoaceticus complex (73.7%). In conclusion, CLSI breakpoints demonstrated the highest consistency between DD and BMD methods. IMPORTANCE: Cefiderocol is one of the few remaining treatment options for infections caused by carbapenem-resistant Gram-negative bacilli (GNB). Accurate interpretation of susceptibility testing is essential for guiding effective therapy. However, discrepancies among breakpoints established by the Clinical and Laboratory Standards Institute, the European Committee on Antimicrobial Susceptibility Testing, and the U.S. Food and Drug Administration may result in inconsistent interpretations, particularly when using the disk diffusion (DD) method, which is more practical in many clinical laboratories. This study compares the categorical agreement between broth microdilution and DD method interpretations for Gram-negative bacilli across multiple guidelines and highlights the potential for misclassification. It also provides susceptibility data for Burkholderia cepacia and Elizabethkingia anophelis, for which established interpretive criteria are currently lacking.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Lin Y-T, Lin H-H, Chen C-H, et al. Interpretive agreement of susceptibility between broth microdilution and disk diffusion methods for cefiderocol, using criteria from the Clinical and Laboratory Standards Institute, European Committee on Antimicrobial Susceptibility Testing, and the Food and Drug Administration. J Clin Microbiol. 2025. PMID: 41369533. doi:10.1128/jcm.01255-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。